Healthcare / Medical DevicesNasdaqCM
$3.72
+0.17 (+4.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.1M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$32M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-51.0%
↓Gross Margin
56.5%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+81.7%
FCF CAGR
—
FCF margin
-32.1%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.1M · net income $-3.6M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $9.1M | $9.1M | $3.5M | $2.0M | $171169.00 | $178146.00 | — | — | — | — | $0.00 | $0.00 | $773.00 | $1249.00 | $921.00 | $5398.00 | $1167.00 |
| Net Income | $-3.6M | $-3.6M | $-12.3M | $-11.9M | $-10.0M | $-9.9M | $-13.6M | $-6.8M | — | — | $-47775.00 | $-62863.00 | $-36244.00 | $-30554.00 | $-13960.00 | $-27604.00 | $-6044.00 |
| EBITDA | $-3.0M | $-3.0M | $-11.8M | $-11.7M | $-9.9M | $-10.1M | $-4.9M | $-5.8M | — | — | — | — | — | — | — | — | — |
| EPS | -0.54 | -0.54 | -2.76 | -3.90 | -3.78 | -5.58 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 56.5% | 56.5% | 31.3% | 23.4% | -41.4% | -54.9% | — | — | — | — | — | — | — | 560.0% | 100.0% | 60.4% | 100.0% |
| Operating Margin | -46.5% | -46.5% | -344.3% | -612.3% | -5860.2% | -5735.9% | — | — | — | — | — | — | -4646.1% | -2009.0% | -1491.1% | — | — |
| Net Margin | -39.6% | -39.6% | -356.7% | -607.4% | -5842.0% | -5584.3% | — | — | — | — | — | — | -4688.7% | -2446.3% | -1515.7% | -511.4% | -517.9% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.32 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 4.38 | 4.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-2.9M | $-2.9M | $-11.1M | $-13.3M | $-7.8M | $-8.7M | $-3.5M | $-5.5M | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -51.0% | -51.0% | -1498.5% | -189.8% | -104.1% | -151.8% | -660.2% | 547.9% | — | — | 17.9% | 77.1% | 102.4% | 100.9% | 81.0% | 842.4% | 139.8% |
| Valuation | |||||||||||||||||
| P/B | 3.52 | 3.52 | 31.19 | 2.55 | 2.45 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 163.5% | 163.5% | 76.9% | 1040.7% | — | — | — | — | — | — | — | -100.0% | -38.1% | 35.6% | -82.9% | 362.6% | — |
| EPS Growth | 80.4% | 80.4% | 29.2% | -3.2% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.76 → -0.54
Residual
+1.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.